Literature DB >> 18708196

Angiogenesis and tumor progression in neuroendocrine digestive tumors.

Gilles Poncet1, Karine Villaume, Thomas Walter, Céline Pourreyron, Aurélie Theillaumas, Florian Lépinasse, Valérie Hervieu, Martine Cordier-Bussat, Jean-Yves Scoazec, Colette Roche.   

Abstract

BACKGROUND: Clinical observations suggest that in neuroendocrine digestive tumors a high intratumoral microvascular density is associated with good prognosis. We used an experimental orthotopic xenograft model to analyze the relations between angiogenic activity and tumor progression in this tumor subset.
MATERIAL AND METHODS: We compared 2 endocrine cell lines: STC-1, a low vascular endothelial growth factor (VEGF)-producing cell line, and INS-r3, a high VEGF-producing cell line. Tumor cells were grafted in the adventitial layer of the caecal wall of nude mice, sacrificed after 8 wk.
RESULTS: At 8 wk, "primary" tumors were present in all animals. STC-1 derived tumors were morphologically moderately differentiated, with high proliferative and apoptotic activities; in contrast, INS-r3 derived tumors were well differentiated, with low proliferative and apoptotic activities. VEGF was expressed in <50% grafted STC-1 cells but in >90% of grafted INS-r3 cells. Microvascular density was significantly higher in INS-r3 derived tumors than in STC-1 derived tumors. All STC-1 derived tumors (n = 8) have invaded the mucosa, in contrast to none of the INS-r3 derived tumors (n = 8); liver metastases were detected in 7/8 animals bearing STC-1 derived tumors and in 0/8 animals with INS-r3 derived tumors, despite the presence of lymph node metastases.
CONCLUSIONS: Our experimental data concur with clinical findings to suggest that in well differentiated digestive neuroendocrine tumors angiogenesis is disconnected from tumor progression: the development of a highly vascular tumor microenvironment is correlated with VEGF secretion but is not associated with invasive and metastatic properties; it must therefore be regarded as an indirect marker of differentiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708196     DOI: 10.1016/j.jss.2008.03.055

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  12 in total

Review 1.  Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.

Authors:  P Gajate; T Alonso-Gordoa; O Martínez-Sáez; J Molina-Cerrillo; E Grande
Journal:  Clin Transl Oncol       Date:  2017-11-09       Impact factor: 3.405

Review 2.  Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.

Authors:  Omar Abdel-Rahman
Journal:  Tumour Biol       Date:  2014-09-18

3.  Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth.

Authors:  Christophe Couderc; Gilles Poncet; Karine Villaume; Martine Blanc; Nicolas Gadot; Thomas Walter; Florian Lepinasse; Valérie Hervieu; Martine Cordier-Bussat; Jean-Yves Scoazec; Colette Roche
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 4.  Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.

Authors:  Omar Abdel-Rahman; Mona Fouad
Journal:  Tumour Biol       Date:  2015-01-18

5.  Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors.

Authors:  Patricia Kuiper; Lukas Jac Hawinkels; Eveline Sm de Jonge-Muller; Izäk Biemond; Cornelis Bhw Lamers; Hein W Verspaget
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

Review 6.  Current understanding of the molecular biology of pancreatic neuroendocrine tumors.

Authors:  Jianliang Zhang; Rony Francois; Renuka Iyer; Mukund Seshadri; Maria Zajac-Kaye; Steven N Hochwald
Journal:  J Natl Cancer Inst       Date:  2013-07-09       Impact factor: 13.506

7.  Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.

Authors:  Gerard V Walls; Anita A C Reed; Jeshmi Jeyabalan; Mahsa Javid; Nathan R Hill; Brian Harding; Rajesh V Thakker
Journal:  Endocrinology       Date:  2012-09-28       Impact factor: 4.736

8.  Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.

Authors:  Wen-Chi Chou; Po-Han Lin; Yi-Chen Yeh; Yi-Ming Shyr; Wen-Liang Fang; Shin-E Wang; Chun-Yu Liu; Peter Mu-Hsin Chang; Ming-Han Chen; Yi-Ping Hung; Chung-Pin Li; Yee Chao; Ming-Huang Chen
Journal:  Int J Biol Sci       Date:  2016-11-25       Impact factor: 6.580

9.  Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Rossana Berardi; Mariangela Torniai; Stefano Partelli; Corrado Rubini; Silvia Pagliaretta; Agnese Savini; Vanessa Polenta; Matteo Santoni; Riccardo Giampieri; Sofia Onorati; Federica Barucca; Alberto Murrone; Francesca Bianchi; Massimo Falconi
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

10.  The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors.

Authors:  Julien Bollard; Patrick Massoma; Cécile Vercherat; Martine Blanc; Florian Lepinasse; Nicolas Gadot; Christophe Couderc; Gilles Poncet; Thomas Walter; Marie-Odile Joly; Valérie Hervieu; Jean-Yves Scoazec; Colette Roche
Journal:  Oncotarget       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.